Please ensure Javascript is enabled for purposes of website accessibility

Why Veru Stock Is Vaulting Higher Today

By Keith Speights - May 13, 2020 at 10:48AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors liked the drugmaker's positive Q1 update. And they liked its news about a COVID-19 clinical study even more.

What happened

Shares of Veru (VERU 19.18%) were vaulting 15.6% higher as of 11:22 a.m. EDT on Wednesday. The big jump came after the biopharmaceutical company provided its first-quarter update after the market closed on Tuesday. Veru also announced that it had received a green light from the FDA to begin a phase 2 clinical trial evaluating VERU-111 in treating COVID-19

So what

Veru reported that its Q1 revenue jumped 43% year over year to $9.9 million with climbing sales of its FC2 female condom. The company's gross profit soared 61% to $7.4 million. However, Veru posted a net loss in the first quarter of $0.01 per share.

Gloved hand in front of wood blocks that are standing with fallen blocks that spell COVID-19

Image source: Getty Images.

The bigger story for the company was its announcement about VERU-111. The experimental drug is already being evaluated in a phase 2 study targeting metastatic castration-resistant prostate cancer. Why would a prostate cancer drug potentially be effective in treating COVID-19? It's a little complicated.

VERU-111 targets microtubules that transport viruses. The idea is that the drug could disrupt the microtubule traffic that the novel coronavirus uses to cause infection. In addition, VERU-111 has anti-inflammatory effects that might be able to reduce the inflammation in COVID-19 patients that's caused by cytokine storms, an immune response whereby the body attacks its own cells. 

Now what

Today's surge for Veru could prove to be only a temporary one. However, the company plans to begin dosing patients within the next two weeks, with treatment to go on for 21 days. It shouldn't be long before data is available to show if there's significant potential for VERU-111 in treating COVID-19.

Veru is also seeking grant funding from the Biomedical Advanced Research and Development Authority (BARDA) and the Defense Advanced Research Projects Agency (DARPA). If the drugmaker obtains funding, its share price could enjoy another boost.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

The Female Health Company Stock Quote
The Female Health Company
VERU
$19.08 (19.18%) $3.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.